Please login to the form below
Versartis
This page shows the latest Versartis news and features for those working in and with pharma, biotech and healthcare.
Versartis crashes as VELOCITY trial veers off track
The US biotech's somavaratan proved inferior to Pfzier’s Genotropin. US biotech Versartis saw more than 80% wiped off its share price ahead of the weekend after its growth hormone ... Versartis disappointment has proved a fillip for rival company
Latest news
-
Pfizer/Opko's long-acting growth hormone misses mark in trial
Also in the running is Versartis, whose somavaratan (VRS-317) is in late-stage trials and was recently licensed to Teijin in Japan.
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
Latest Intelligence
-
Deal Watch August 2016
252. Versartis. Teijin (JP). Licence Japan. Somavaratan, long-acting form of rhGH, for paediatric and adult growth hormone deficiency in phase II/III in Japan.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Versartis names chief financial officer
Joshua Brumm joins from Pharmacyclics. Versartis has named Joshua Brumm as its first chief financial officer. ... The company's CEO Dr Jeffrey Cleland said: "His appointment comes during a particularly exciting stage of development for Versartis and will
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Account Director – UK Office
-
Excellent salary and benefits
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Account Director - Medical Communications - London / South East
-
Excellent Salary and Benefits on offer
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- Account Director, Healthcare Communications
-
Salary TBC
- FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...
-
Excellent Daily Rate
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
Subscribe to our email news alerts
- The relevance of patient perspectives to value
- Sanofi patent case win holds off generic rivals for key cancer drug
- Leo Pharma to market AstraZeneca’s brodalumab outside Europe
- Regeneron scores positive data in phase 3 cholesterol trial
- Roche undercuts price of Bayer cancer drug after winning FDA approval
- Putting our core values into practice at the Porterhouse summer social
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- The relevance of patient perspectives to value
- Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
- How is the NHS Long-term Plan being put into action?
- Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
- The evolution of real-world studies
- How industry and regulators are using real-world data...
Quick links
Infographics
